ArticleNutrition & metabolism2026
Insulin signaling pathway related m
Article in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDeficiency of insulin signaling components may act as the underlying mechanisms for insulin resistance and type 2 diabetes (T2D). N6-methyladenosine (m6A) is emerging as an important regulatory mechanism in gene expression at the post-transcriptional level. This study aimed to identify the insulin signaling pathway related m6A methylated biomarker for early detection of T2D.
methodsCandidate genes (PIK3CA and AKT1) with abnormal m6A modification in insulin signaling pathway and the potential methylase (FTO) were selected and validated. Luciferase assay was used to investigate the interaction between FTO and PIK3CA/AKT1. The mechanism of FTO on m6A modification of PIK3CA was validated by methylated RNA immunoprecipitation (MeRIP), western-blot and glucose metabolism assays. The clinical significance of m6A methylated PIK3CA was evaluated in a nested case-control study.
resultsWe found that the m6A content and mRNA expression of PIK3CA were significantly downregulated and FTO mRNA expression was significantly upregulated in T2D cases and prediabetes, compared with controls. Mechanism analysis demonstrated that FTO overexpression significantly reduced the m6A level, total mRNA and protein expression of PIK3CA, subsequently inhibited glucose consumption and glucose metabolism. m6A methylated PIK3CA can significantly improve the predictive ability of T2D occurrence beyond traditional risk factors alone.
conclusionDecreased m6A level of PIK3CA promote abnormal glucose metabolism and T2D development by reducing PIK3CA mRNA expression, which was under the control of FTO-mediated m6A modification. m6A methylated PIK3CA is a valuable biomarker for prediction and early detection of T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.